RESUMO
The plant of Paeonia lactiflora Pall. belongs to Ranunculaceae, and its root can be divided into two categories according to different processing methods, which included that one was directly dried without peeling the root of the P. lactiflora (PR), and the other was peeled the root of the P. lactiflora (PPR) after boiled and dried. To evaluate the difference of chemical components, UPLC-ESI-Q-Exactive Focus-MS/MS and UPLC-QQQ-MS were applied. The distribution of chemical components in different tissues was located by laser microdissection (LMD), especially the different ingredients. A total of 86 compounds were identified from PR and PPR. Four kind of tissues were isolated from the fresh root of the P. lactiflora (FPR), and 54 compounds were identified. Especially the content of gallic acid, albiflorin, and paeoniflorin with high biological activities were the highest in the cork, but they were lower in PR than that in PPR, which probably related to the process. To illustrate the difference in pharmacological effects of PR and PPR, the tonifying blood and analgesic effects on mice were investigated, and it was found that the tonifying blood and analgesic effects of PPR was superior to that of PR, even though PR had more constituents. The material basis for tonifying blood and analgesic effect of the root of P. lactiflora is likely to be associated with an increase in constituents such as paeoniflorin and paeoniflorin lactone after boiled and peeled. The study was likely to provide some theoretical support for the standard and clinical application.
Assuntos
Glucosídeos , Monoterpenos , Paeonia , Raízes de Plantas , Animais , Masculino , Camundongos , Analgésicos/farmacologia , Analgésicos/química , Analgésicos/análise , Hidrocarbonetos Aromáticos com Pontes , Cromatografia Líquida de Alta Pressão/métodos , Medicamentos de Ervas Chinesas/química , Medicamentos de Ervas Chinesas/farmacologia , Ácido Gálico/análise , Ácido Gálico/química , Glucosídeos/análise , Glucosídeos/química , Lasers , Espectrometria de Massa com Cromatografia Líquida , Microdissecção/métodos , Monoterpenos/farmacologia , Monoterpenos/análise , Monoterpenos/química , Paeonia/química , Extratos Vegetais/química , Extratos Vegetais/farmacologia , Raízes de Plantas/química , Espectrometria de Massas por Ionização por Electrospray/métodos , Espectrometria de Massas em Tandem/métodosRESUMO
Two selective, sensitive and environmentally safe LC methods were developed and validated for determination of paracetamol, caffeine, ergotamine tartrate and metoclopramide in coformulated antimigraine tablets along with p-aminophenol, p-nitrophenol and theophylline as officially specified impurities. The first is based on high-performance thin-layer chromatography (HPTLC) coupled with densitometric quantitation. Separation was achieved on HPTLC silica gel 60 F254 plates as stationary phase using ethyl acetate:aqueous ammonium hydroxide solution:glacial acetic acid (10.0:0.4:0.1, by volume) as a developing system followed by scanning of the separated bands at 210.0 nm. The subsequent method depends on HPLC with diode array detection. The LC separation was accomplished on a Scharlau C18 (250 × 4.6 mm, 5 µm) column using a mixture of 20.0 mm sodium dihydrogen phosphate, pH 3.0, adjusted with o-phosphoric acid and methanol, at a flow rate of 1.3 mL/min in a gradient elution program. The separated peaks were detected at 210.0 nm. The proposed methods have been validated and proven to meet the requirements outlined in the International Council for Harmonisation (ICH) guidelines. The greenness profile evaluation was carried out using three tools, namely, the National Environmental Method Index, the Analytical EcoScale and the Green Analytical Procedure Index tool, and a comparative study was then conducted. Successful application of the developed methods for determination of the cited quaternary mixture in Metograine tablets confirms their suitability regarding the analytical performance and ecological impact in quality control assay and impurity profiling purposes.
Assuntos
Analgésicos , Cromatografia Líquida de Alta Pressão/métodos , Contaminação de Medicamentos , Química Verde/métodos , Analgésicos/análise , Analgésicos/química , Cromatografia em Camada Fina/métodos , Combinação de Medicamentos , Humanos , Limite de Detecção , Modelos Lineares , Transtornos de Enxaqueca , Reprodutibilidade dos Testes , Comprimidos/químicaRESUMO
BACKGROUND: There is strong evidence of under-reporting of harms in manuscripts on randomized controlled trials (RCTs) compared with the volume of raw data retrieved from these trials. Many guidelines have been developed to tackle this, but they have failed to address some important issues that would allow for standardization and transparency. As a consequence, harms reporting in manuscripts remains suboptimal. OBJECTIVE: The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) aimed to deliver accurate recommendations for better reporting of harms in clinical trials manuscripts on anti-osteoarthritis (OA) drugs. These could help to better inform clinicians on harms recorded in RCTs and further help researchers conducting meta-analyses. METHODS: Using the outcomes of several systematic reviews on the safety of anti-OA drugs, we summarized the ways in which harms have been reported in OA RCT manuscripts to date. Next, we drafted some recommendations and initiated a modified Delphi process that involved a panel of clinicians and clinical researchers to build an expert consensus on recommendations from the ESCEO for the reporting of harms in future manuscripts on RCTs assessing anti-OA drugs. RESULTS: These recommendations emphasize that all treatment-emergent adverse events (AEs) should always be taken into account for harms reporting, with no frequency threshold, and describe how specific AEs should be reported; they also provide a list of the most relevant organ systems to be considered according to each class of drug for reporting of harms within the results section of a manuscript. Irrespective of the drug, the ESCEO recommends that total, severe and serious AEs and withdrawals due to AEs should always be reported; guidance on the reporting of specific events pertaining to each category is provided. The ESCEO also recommends the reporting of information on drug effect on biological parameters, with specific guidance. CONCLUSIONS: These recommendations may contribute to improve transparency in the field of safety of anti-OA medications. Pharmaceutical companies developing drugs for OA, and researchers conducting clinical trials, are encouraged to comply with them when reporting harms-related results in manuscripts on RCTs. The ESCEO also encourages journals to refer to the ESCEO recommendations in their instructions to authors for the publication of manuscripts on trials of anti-OA medications.
Assuntos
Sistemas de Notificação de Reações Adversas a Medicamentos/normas , Analgésicos/efeitos adversos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/prevenção & controle , Osteoartrite/tratamento farmacológico , Osteoporose/tratamento farmacológico , Ensaios Clínicos Controlados Aleatórios como Assunto/normas , Analgésicos/análise , Analgésicos/uso terapêutico , Consenso , Europa (Continente) , Guias como Assunto , Humanos , Osteoartrite/economia , Osteoporose/economia , Avaliação de Resultados em Cuidados de Saúde , Sociedades MédicasRESUMO
The objective is using saliva instead of plasma for pregabalin therapeutic drug monitoring (TDM) since saliva reflects the free non-protein bound drug concentration, simple and noninvasive sampling, cheaper and does not require the expertise of drawing blood. Forty four patients participated in this study, two samples of saliva and another two of blood were taken from each patient; first sample of both saliva and blood is the trough sample and was taken just before the first dose of the day and second sample is the peak sample and was taken 1 h after taking the first dose of the day. Descriptive statistics and t-testing after log transformation were done using Excel, p-value=0.05 was adopted for significant difference. Optimized effective intestinal permeability of pregabalin was estimated by PK-Sim program version 7. This study for the first time revealed that pregabalin is excreted in saliva and classified as class 1 based on Salivary Excretion Classification System (SECS). A good correlation of 0.71-0.83 between Cmin and Cmax of plasma and saliva pregabalin was observed respectively which indicate that saliva sampling is a good alternative matrix for pregabalin TDM. C/D-ratios were calculated to demonstrate pharmacokinetic variability of Pregabalin; the results showed that C/D-ratio was higher in women, elderly and in those patients who had Scr.≥0.9 mg/dl. Proposed pregabalin therapeutic ranges are 0.7 to 1.84 µg/ml in plasma and 0.055 to 0.145 µg/ml in saliva, for neuropathic pain, diabetic neuropathy and disc prolapse patients.
Assuntos
Analgésicos/análise , Monitoramento de Medicamentos/métodos , Pregabalina/análise , Saliva/química , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Analgésicos/sangue , Analgésicos/farmacocinética , Analgésicos/uso terapêutico , Variação Biológica da População , Monitoramento de Medicamentos/economia , Feminino , Humanos , Mucosa Intestinal/metabolismo , Jordânia , Masculino , Pessoa de Meia-Idade , Dor/tratamento farmacológico , Permeabilidade , Pregabalina/sangue , Pregabalina/farmacocinética , Pregabalina/uso terapêutico , Eliminação Salivar , Fatores Sexuais , Adulto JovemRESUMO
BACKGROUND: The detection and analysis of drugs in hair has progressively emerged as a consequence of the enhanced sensitivity of analytical techniques used in forensic toxicology; a greater advantage in using this matrix respect to classical ones (i.e., urine and blood) is an easier and noninvasive sample collection, even when the careful supervision of law-enforcement officers is required to avoid the risk that the sample may be adulterated or replaced. Moreover, according to the length of the hair, the history of drug exposure can be retrospectively monitored from few weeks up to months or years since sample collection. OBJECTIVE: Given the potential negative effects of pregabalin, an antiepileptic and analgesic drug with a high risk of misuse and abuse, the laboratory was asked to test for the drug in hair. METHOD: A new ultrahigh-performance liquid chromatography coupled to tandem mass spectrometry was developed. The method involves incubation of 25 mg of cut hair in acetonitrile for 2 h in an ultrasonic bath and separation on an Acquity HSS C18 column (150 × 2.1 mm × 1.8 µm) maintained at 50°C in a thermostatically controlled oven. A gradient elution was performed. RESULTS: The method was fully validated according to international standards. The limit of quantitation of the test was 10 pg/mg. Five authentic cases of pregabalin in hair segments were tested using the method and the results were in the range 17-1487 pg/mg. CONCLUSION: This new method was found suitable to monitor both patients under pregabalin therapy and dependent subjects.
Assuntos
Cabelo/química , Pregabalina/análise , Detecção do Abuso de Substâncias/métodos , Analgésicos/análise , Cromatografia Líquida , Feminino , Humanos , Limite de Detecção , Masculino , Reprodutibilidade dos Testes , Espectrometria de Massas em TandemRESUMO
The occurrence of seven pharmaceuticals and two metabolites belonging to non-steroidal anti-inflammatory drugs and analgesics therapeutic classes was studied in seawaters. A total of 101 samples covering fourteen beaches and five cities were evaluated in order to assess the spatial distribution of pharmaceuticals among north Portuguese coast. Seawaters were selected in order to embrace different bathing water quality (excellent, good and sufficient). Acetaminophen, ketoprofen and the metabolite hydroxyibuprofen were detected in all the seawater samples at maximum concentrations of 584, 89.7 and 287 ng L(-1), respectively. Carboxyibuprofen had the highest seawater concentration (1227 ng L(-1)). The temporal distribution of the selected pharmaceuticals during the bathing season showed that, in general, higher concentrations were detected in August and September. The environmental risk posed by the pharmaceuticals detected in seawaters towards different trophic levels (fish, daphnids and algae) was also assessed. Only diclofenac showed hazard quotients above one for fish, representing a potential risk for aquatic organisms. These results were observed in seawaters classified as excellent bathing water. Additional data is needed in order to support the identification and prioritization of risks posed by pharmaceuticals in marine environment.
Assuntos
Analgésicos/análise , Anti-Inflamatórios não Esteroides/análise , Monitoramento Ambiental , Água do Mar/química , Poluentes Químicos da Água/análise , Portugal , Medição de RiscoRESUMO
OBJECTIVE: To assess the analgesic and anti-inflammatory effects of Tongjingbao optimal formula and analyze its active components. METHOD: Animals were divided into the model group, the Tongjingbao granule group and the Tongjingbao optimal formula group. The mice dysmenorrhea model was induced by oxytocin, and their content of blood calcium and MDA, NO, PGE2 in uterus were determined to assess the analgesic and anti-inflammatory effects of different components in Tongjingbao optimal formula and their impacts. RESULT: All components of Tongjingbao optimal formula could extend the dysmenorrhea incubation period of mice with dysmenorrhea, reduce their average writhing time, increase the writhing inhibition rate, lessen the content of blood calcium and MDA, PGE2 in uterus, and enhance the content of NO in uterus. CONCLUSION: All components of Tongjingbao optimal formula have the analgesic and anti-inflammatory effects, and different components show a synergistic effect in treating dysmenorrheal in many links.